Skip to main content
Top
Published in: Gastric Cancer 5/2020

01-09-2020 | Gastric Cancer | Original Article

Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells

Authors: Jung Hwan Yoon, Hassan Ashktorab, Duane T. Smoot, Suk Woo Nam, Hoon Hur, Won Sang Park

Published in: Gastric Cancer | Issue 5/2020

Login to get access

Abstract

Background

Gastrokine 1 (GKN1) is a stomach-specific tumor suppressor that is secreted into extracellular space as an exosomal cargo protein. The objective of this study was to investigate the uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells.

Methods

Immunofluorescent and Western blot analysis were used to investigate gastric-specific uptake of HFE-145-derived exosomes. Binding affinity of HFE-145 derived exosomes with integrin proteins was examined using protein microarray chip. Tumor suppressor activities of exosome-carrying GKN1 protein were analyzed using transwell co-culture, MTT assay, BrdU incorporation, immunoprecipitation, and Western blot analysis.

Results

HFE-145-derived exosomes were internalized only into HFE-145 gastric epithelial cells and gastric cancer cells. Gastric-specific uptake of stomach-derived exosomes required integrin α6 and αX proteins. Clathrin and macropinocytosis increased the uptake of exosomes into gastric epithelial cells, whereas caveolin inhibited the uptake of exosomes. Transwell co-culture of AGS cells with HFE-145 cells markedly inhibited viability and proliferation of AGS cells. Following uptake of HFE-145-derived exosomes in recipient cells, GKN1 protein bound to HRas and inhibited the binding of HRas to b-Raf and c-Raf which subsequently downregulated HRas/Raf/MEK/ERK signaling pathways in AGS, MKN1 cells, and MKN1-derived xenograft tumor tissues. In addition, exosomal GKN1 protein suppressed both migration and invasion of gastric cancer cells by inhibiting epithelial–mesenchymal transition.

Conclusions

Gastric-specific uptake of exosomes derived from gastric epithelial cells requires integrin α6 and αX proteins in both gastric epithelial cells and exosomes. Exosomal GKN1 protein inhibits gastric carcinogenesis by downregulating HRas/Raf/MEK/ERK signaling pathways.
Appendix
Available only for authorised users
Literature
11.
go back to reference Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010;11(5):675–87 (Epub 2010/02/09).CrossRef Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010;11(5):675–87 (Epub 2010/02/09).CrossRef
20.
go back to reference Xing R, Cui JT, Xia N, Lu YY. GKN1 inhibits cell invasion in gastric cancer by inactivating the NF-kappaB pathway. Discov Med. 2015;19(103):65–71 (Epub 2015/03/01).PubMed Xing R, Cui JT, Xia N, Lu YY. GKN1 inhibits cell invasion in gastric cancer by inactivating the NF-kappaB pathway. Discov Med. 2015;19(103):65–71 (Epub 2015/03/01).PubMed
21.
go back to reference Yoon JH, Choi WS, Kim O, Park WS. The role of gastrokine 1 in gastric cancer. J Gastric Cancer. 2014;14(3):147–55. doi: 10.5230/jgc.2014.14.3.147. (Epub 2014/10/21) Yoon JH, Choi WS, Kim O, Park WS. The role of gastrokine 1 in gastric cancer. J Gastric Cancer. 2014;14(3):147–55. doi: 10.5230/jgc.2014.14.3.147. (Epub 2014/10/21)
34.
go back to reference Wei F, Yan J, Tang D. Extracellular signal-regulated kinases modulate DNA damage response–a contributing factor to using MEK inhibitors in cancer therapy. Curr Med Chem. 2011;18(35):5476–82 (Epub 2011/11/18).CrossRef Wei F, Yan J, Tang D. Extracellular signal-regulated kinases modulate DNA damage response–a contributing factor to using MEK inhibitors in cancer therapy. Curr Med Chem. 2011;18(35):5476–82 (Epub 2011/11/18).CrossRef
35.
go back to reference Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 1998;95(7):3537–42. https://doi.org/10.1073/pnas.95.7.3537 (Epub 1998/05/09).CrossRefPubMed Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 1998;95(7):3537–42. https://​doi.​org/​10.​1073/​pnas.​95.​7.​3537 (Epub 1998/05/09).CrossRefPubMed
Metadata
Title
Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells
Authors
Jung Hwan Yoon
Hassan Ashktorab
Duane T. Smoot
Suk Woo Nam
Hoon Hur
Won Sang Park
Publication date
01-09-2020
Publisher
Springer Singapore
Published in
Gastric Cancer / Issue 5/2020
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-020-01068-2

Other articles of this Issue 5/2020

Gastric Cancer 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.